Author(s):
Sarah Khallad, Eyad Mallah, Luay Abu-Qatouseh, Ahmad Abu-awwad, Kenza Mansoor, Shada Abutaleb, Khaled W. Omari, Hanna Dib, Tawfiq Arafat
Email(s):
sarahkhallad4@gmail.com , emallah@uop.edu.jo , labuqatouseh@uop.edu.jo , a.awwad@jpu.edu.jo , kmansoor@uop.edu.jo , shadaabutaleb@yahoo.com , khaled.omari@aum.edu.kw , hanna.dib@aum.edu.kw , t.arafat@jcpr-jo.com
DOI:
10.52711/0974-360X.2025.00759 
Address:
Sarah Khallad1, Eyad Mallah1, Luay Abu-Qatouseh1, Ahmad Abu-awwad2, Kenza Mansoor1, Shada Abutaleb1, Khaled W. Omari3, Hanna Dib3, Tawfiq Arafat4
1Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.
2Faculty of Pharmacy, Jerash University, Jerash, Jordan.
3College of Engineering and Technology, American University of the Middle East, Kuwait.
4Jordan Center for Pharmaceutical Research, Amman, Jordan.
*Corresponding Author
Published In:
Volume - 18,
Issue - 11,
Year - 2025
ABSTRACT:
Carbamazepine is a medication used to treat neurodevelopmental disorders like epilepsy and autism spectrum disorder (ASD). Although pharmacogenomic research may provide useful results, there are not many, particularly for adults. This study aimed to evaluate the therapeutic efficacy of carbamazepine. Carbamazepine steady-state concentrations were determined using a previously designed and validated LC-MS/MS technique. Genomic DNA was extracted. Genetic polymorphisms in their SULT1A1, CYP2D6*4, CYP2D6*10, CYP2C19, and CYP3A5 genes were identified using a conventional PCR. These people's clinical biochemistry test results, treatment plans, and demographic information were gathered. Abnormal biochemical test results were found in some individuals, including hematology, liver enzymes, and insufficient 25-Hydroxyvitamin D3 levels. Regular therapeutic medication monitoring is necessary to customize dosage schedules for pharmacological therapy that is both safe and effective for people with ASD/ID. The Statistical Package for the Social Sciences (SPSS) was used for statistical analysis. This study is one of the first global pharmacogenomics studies to include individuals with ASD or ID. Despite the absence of a correlation between genotyping of drug-metabolizing enzymes and CBZ plasma concentrations, implementation of genotype-guided drug therapy can offer novel contributions to maximize drug efficacy and minimize toxicity, given the limited amount of pharmacogenomics studies on this population for adults.
Cite this article:
Sarah Khallad, Eyad Mallah, Luay Abu-Qatouseh, Ahmad Abu-awwad, Kenza Mansoor, Shada Abutaleb, Khaled W. Omari, Hanna Dib, Tawfiq Arafat. Clinical Care Monitoring for patients with Neurodevelopmental disorders administered with Carbamazepine associated with CYP and SULT genes. Research Journal Pharmacy and Technology. 2025;18(11):5267-4. doi: 10.52711/0974-360X.2025.00759
Cite(Electronic):
Sarah Khallad, Eyad Mallah, Luay Abu-Qatouseh, Ahmad Abu-awwad, Kenza Mansoor, Shada Abutaleb, Khaled W. Omari, Hanna Dib, Tawfiq Arafat. Clinical Care Monitoring for patients with Neurodevelopmental disorders administered with Carbamazepine associated with CYP and SULT genes. Research Journal Pharmacy and Technology. 2025;18(11):5267-4. doi: 10.52711/0974-360X.2025.00759 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-21
REFERENCES:
1. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, Jones EJ, Jones RM, Pickles A, State MW, Taylor JL. Autism spectrum disorder. Nature Reviews Disease primers. 2020; Jan 16; 6(1): 1-23. doi: 10.1038/s41572-019-0138-4
2. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry. 2008; Aug 1; 47(8): 921-9. doi: 10.1097/CHI.0b013e318179964f
3. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Archives of Pediatrics and Adolescent Medicine. 2006; Aug 1; 160(8): 825-30. doi: 10.1001/archpedi.160.8.825
4. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome p450–mediated drug-drug interactions in older hospitalized patients with polypharmacy. Annals of Pharmacotherapy. 2013; Mar; 47(3): 324-32. doi: 10.1345/aph.1R621
5. Ballester P, Espadas C, Londoño AC, Almenara S, Aguilar V, Belda C, Pérez E, Muriel J, Peiró AM. The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability. Autism Research. 2022 Jan;15(1):192-202. doi: 10.1002/aur.2624
6. Panday DR, Panday KR, Basnet M, Kafle S, Shah B, Rauniar GP. Therapeutic drug monitoring of carbamazepine. Int J Neurorehabilitation Eng. 2017; 4(245): 2376-0281. doi: 10.4172/2376-0281.1000245
7. Iivanainen M. Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability. Journal of Intellectual Disability Research: JIDR. 1998; Dec 1; 42: 24-31. PMID: 10030428
8. McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, Malhi GS, Nierenberg AA, Rosenblat JD, Majeed A, Vieta E. Bipolar disorders. The Lancet. 2020; Dec 5; 396(10265): 1841-56.
9. Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Practical Neurology. 2021; 21(5): 392-402. doi: 10.1111/eip.12930
10. Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Therapeutic Drug Monitoring. 2018; Oct 1; 40(5): 526-48. doi: 10.1097/FTD.0000000000000546
11. Youngster I, Zachor DA, Gabis LV, Bar‐Chaim A, Benveniste‐Levkovitz P, Britzi M, Soback S, Ziv‐Baran T, Berkovitch M. CYP 2D6 genotyping in paediatric patients with autism treated with risperidone: A preliminary cohort study. Developmental Medicine and Child Neurology. 2014; Oct; 56(10): 990-4. doi: 10.1111/dmcn.12470
12. Pachouri SS, Sobti RC, Kaur P, Singh J, Gupta SK. Impact of polymorphism in sulfotransferase gene on the risk of lung cancer. Cancer Genetics and Cytogenetics. 2006; Nov 1; 171(1): 39-43. doi: 10.1016/j.cancergencyto.2006.06.017
13. Arslan S, Silig Y, Pinarbasi H. An investigation of the relationship between SULT1A1 Arg213His polymorphism and lung cancer susceptibility in a Turkish population. Cell Biochemistry and Function: Cellular Biochemistry and its Modulation by Active Agents or Disease. 2009; Jun; 27(4): 211-5. doi: 10.1002/cbf.1558
14. Qatouseh LA, Sabri I, Alkhatib I, Atwa E, Arafat T. Detection of high-risk human papillomavirus genotypes 16 and 18 in head and neck squamous cell carcinomas in Jordan. Asian Pacific Journal of Cancer Prevention: APJCP. 2017; 18(5): 1337. doi: 10.22034/APJCP.2017.18.5.1337
15. Thota K, Prasad KB, Rao MV. Detection of cytochrome P450 polymorphisms in breast cancer patients may impact on tamoxifen therapy. Asian Pacific Journal of Cancer Prevention: APJCP. 2018; 19(2): 343. doi: 10.22034/APJCP.2018.19.2.343
16. Gunes S, Ekinci O, Celik T. Iron deficiency parameters in autism spectrum disorder: clinical correlates and associated factors. Italian Journal of Pediatrics. 2017; Dec; 43: 1-6. doi: 10.1186/s13052-017-0407-3
17. Ayano G. Bipolar disorders and carbamazepine: pharmacokinetics, pharmacodynamics, therapeutic effects and indications of carbamazepine: review of articles. J Neuropsychopharmacol Ment Health. 2016; Aug 22; 1(112): 2. doi: 10.4172/2472-095X.1000112
18. Cepelak I, Grubišić TŽ, Mandušić A, Rekić B, Leniček J. Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children. Clinica chimica acta. 1998 Aug 28; 276(2): 121-7. doi: 10.1016/S0009-8981(98)00094-1
19. Strolin Benedetti M, Ruty B, Baltes E. Induction of endogenous pathways by antiepileptics and clinical implications. Fundamental and Clinical Pharmacology. 2005; Oct; 19(5): 511-29. doi: 10.1111/j.1472-8206.2005.00341.x
20. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006; Apr 1; 15(3): 156-64. doi: 10.1016/j.seizure.2005.12.009
21. Fricke-Galindo I, LLerena A, Jung-Cook H, López-López M. Carbamazepine adverse drug reactions. Expert Review of Clinical Pharmacology. 2018; Jul 3; 11(7): 705-18. doi: 10.1080/17512433.2018.1486707
22. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. Journal of Hepatology. 1990; Sep 1; 11(2): 272-6. doi: 10.1016/0168-8278(90)90124-a
23. Haque T, Sasatomi E, Hayashi PH. Drug-induced liver injury: pattern recognition and future directions. Gut and Liver. 2016; Jan; 10(1): 27. doi: 10.5009/gnl15114
24. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. InMayo clinic Proceedings 2014 Jan 1 (Vol. 89, No. 1, pp. 95-106). Elsevier. doi: 10.1016/j.mayocp.2013.09.016
25. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. Journal of Clinical Epidemiology. 1993; Nov 1; 46(11): 1323-30. doi: 10.1016/0895-4356(93)90101-6
26. Smith G. European Medicines Agency guideline on bioanalytical method validation: what more is there to say?. Bioanalysis. 2012; May 1; 4(8): 865-8. doi: 10.4155/bio.12.44
27. Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. British journal of Clinical Pharmacology. 2001; Jun; 51(6): 567-76. doi: 10.1046/j.0306-5251.2001.01396.x
28. Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Therapeutic drug Monitoring. 2018; Oct 1; 40(5): 526-48. doi: 10.1097/FTD.0000000000000546
29. Yoshida K, Koyama E, Zai CC, Beitchman JH, Kennedy JL, Lunsky Y, Desarkar P, Müller DJ. Pharmacogenomic studies in intellectual disabilities and autism spectrum disorder: a systematic review. The Canadian Journal of Psychiatry. 2021; Dec; 66(12): 1019-41. doi: 10.1177/0706743720971950
30. Aman MG, Paxton JW, Field CJ, Foote SE. Prevalence of toxic anticonvulsant drug concentrations in mentally retarded persons with epilepsy. American Journal of Mental Deficiency. 1986; May 1; 90(6): 643-50. PMID: 3717220
31. Fong SY, Gao Q, Zuo Z. Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review. Evidence‐Based Complementary and Alternative Medicine. 2013; 2013(1): 898261. doi:10.1155/2013/898261
32. Soukhon AA, Abu-Qatouseh L, Mansoor K, El-Hajji FD, Al-Najjar M, Awwad S, Awad R, Omari KW, Mallah E. Cytotoxicity Activity of Graviola Fruit Extract with Carbamazepine and Valproic Acid Show Antagonistic and Indifferent Effects. Asian Pacific Journal of Cancer Prevention: APJCP. 2023; 24(6): 1869. doi: 10.31557/APJCP.2023.24.6.1869
33. Emad RE, Mallah EY, Shahin FA, El-Hajji FD, Dayyih WA, Idkaidek NA, Abu-Qatouseh LU, Jaradat D, Arafat TA. Determination of carbamazepine in rat plasma by using high performance liquid chromatography (HPLC) in presence of some traditional beverages (tamarind, mango, sugarcane, red bull) and its pharmacokinetic applications. Int J Biol Pharm Allied Sci. 2018; 7: 1908-21. doi: 10.31032/IJBPAS/2018/7.11.4561
34. Perucca E. Drug interactions with carbamazepine: An ever expanding list?. Epilepsy Research. 2018; Nov 1; 147: 119-20. doi: 10.1016/j.eplepsyres.2018.08.001
35. Ahn JE, Bathena SP, Brundage RC, Conway JM, Leppik IE, Birnbaum AK. Iron supplements in nursing home patients associated with reduced carbamazepine absorption. Epilepsy Research. 2018; Nov 1; 147: 115-8. doi: 10.1016/j.eplepsyres.2018.07.015
36. Ganzera M, Schneider P, Stuppner H. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. Life Sciences. 2006 Jan 18;78(8):856-61. doi: 10.1016/j.lfs.2005.05.095
37. Cho HJ, Yoon IS. Pharmacokinetic interactions of herbs with cytochrome p450 and p‐glycoprotein. Evidence‐Based Complementary and Alternative Medicine. 2015; 2015(1): 736431. doi: 10.1155/2015/736431
38. Ramaswamy S, Siddiqui Z, Saharan S, Gabel TL, Bhatia SC. Quetiapine-induced hypothyroidism. Journal of Psychiatry and Neuroscience. 2005; Jan; 30(1): 57. PMCID: PMC543843
39. Dawajani S, Sharon E, Copal P, Prema R. Effect of Sodium Valproate and levetiracetam on thyroid hormones in pediatric patients with epilepsy. Adv in Phar and Clin Trial. 2020; 5(3): 000182. doi: 10.23880/apct-16000182
40. Zhang X, Zhong R, Chen Q, Li M, Lin W, Cui L. Effect of carbamazepine on the bone health of people with epilepsy: a systematic review and meta-analysis. Journal of International Medical Research. 2020; Mar; 48(3): 0300060520902608. doi: 10.1177/0300060520902608
41. Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. The Journal of Steroid Biochemistry and Molecular Biology. 2010; Jul 1; 121(1-2): 467-70. doi: 10.1016/j.jsbmb.2010.03.013
42. Meguid NA, Hashish AF, Anwar M, Sidhom G. Reduced serum levels of 25-hydroxy and 1, 25-dihydroxy vitamin D in Egyptian children with autism. The Journal of Alternative and Complementary Medicine. 2010; Jun 1; 16(6): 641-5. doi: 10.1089/acm.2009.0349
43. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. Journal of Neuroinflammation. 2012; Dec; 9: 1-7. doi: 10.1186/1742-2094-9-201
44. Kočovská E, Fernell E, Billstedt E, Minnis H, Gillberg C. Vitamin D and autism: clinical review. Research in Developmental Disabilities. 2012; Sep 1; 33(5): 1541-50. doi: 10.1016/j.ridd.2012.02.015
45. Gong ZL, Luo CM, Wang L, Shen L, Wei F, Tong RJ, Liu Y. Serum 25-hydroxyvitamin D levels in Chinese children with autism spectrum disorders. Neuroreport. 2014; Jan 8; 25(1): 23-7. doi: 10.1097/WNR.0000000000000034
46. Molloy CA, Kalkwarf HJ, Manning-Courtney P, Mills JL, Hediger ML. Plasma 25 (OH) D concentration in children with autism spectrum disorder. Developmental Medicine and Child Neurology. 2010; Oct; 52(10): 969. doi: 10.1111/j.1469-8749.2010.03704.x
47. Uğur Ç, Gürkan CK. Serum vitamin D and folate levels in children with autism spectrum disorders. Research in Autism Spectrum Disorders. 2014; Dec 1; 8(12): 1641-7. doi: 10.1016/j.rasd.2014.09.002
48. Bener A, Khattab AO, Bhugra D, Hoffmann GF. Iron and vitamin D levels among autism spectrum disorders children. Annals of African Medicine. 2017; Oct 1; 16(4): 186-91. doi: 10.4103/aam.aam_17_17
49. Rastogi H, Sharma G, Sharma A, Jana S. In-Vitro Assessment of the Inhibitory effects of Dietary flavones on the regulated metabolism of CYP 450: Potential for Herb-drug interactions. Research J. Pharm. and Tech. 2020; 13(12): 6086-6092. doi: 10.5958/0974-360X.2020.01061.6
50. Sagar PM, Mankar SD, Dighe SB. An Overview on Analytical Method Development and Validation for Ertugliflozin in Bulk and Pharmaceutical Dosage form. Asian Journal of Pharmaceutical Analysis. 2023; 13(3): 222-8. doi: 10.52711/2231-5675.2023.00036
51. Joseph R, Azeez S, Bhageerathy C. Anticancer effect of sequential extracts from Curcuma caesia rhizomes on human cancer cell lines and characterization of selected polyphenols in active extracts by LC-MS/MS. Asian Journal of Pharmaceutical Research. 2023; 13(4): 219-6. doi: 10.52711/2231-5691.2023.00041
52. Phale MD, Korgaonkar D. Current Advance Analytical Techniques: A Review. Asian J. Research Chem. 2009; 2(3): 235-238.
53. Eswarudu MM, Vinay BK, Srinivasa P. A Review of Analytical Methods for the Estimation of Ivabradine and Metoprolol in Pharmaceutical Formulations and Biological Matrices. Asian Journal of Research in Chemistry. 2022; 15(6): 506-2. doi: 10.52711/0974-4150.2022.00086
54. Ravikkumar VR, Gopal V, Ravichandaran N, Brindha P, Sudha T. Phytochemical Evaluation of Tribal Drug Veerasingam Pattai Zanthoxylum tetraspermum Wight and Arn stem bark. Research J. Pharm. and Tech. 2013; 6(11): 1200-1206.
55. Yugander P, Jagannath M. Structural Neuroimaging Findings in Autism Spectrum Disorder: A Systematic Review. Research Journal of Pharmacy and Technology. 2021; 14(4): 2341-7. doi: 10.52711/0974-360X.2021.00413
56. Srivastava B, Sheeja VK, Haribabu Y, Ebin CJ. Method Development and Validation of Simultaneous Estimation of Emtricitabine and Tenofovir Alafenamide in Bulk and tablet Dosage form using LC-MS/MS. Research Journal of Pharmacy and Technology. 2021; 14(5): 2493-6. doi: 10.52711/0974-360X.2021.00439
57. Laxman DK, More HN. Differences and Similarities in the Metabolism of Erlotinib across various Species: An Analysis by Liquid Chromatography - Tandem Mass Spectrometry. Research Journal of Pharmacy and Technology. 2021; 14(11): 5683-0. doi: 10.52711/0974-360X.2021.00988
58. Jabeen SBV. Simultaneous determination of Cefepime and Tazobactam by using Hyphenated Liquid Chromatography (UPLC-MS/MS). Research Journal of Pharmacy and Technology. 2024; 17(1): 67-3. doi: 10.52711/0974-360X.2024.00011
59. Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. British Journal of Clinical Pharmacology. 2001; Jun; 51(6): 567-76. doi: 10.1046/j.0306-5251.2001.01396.x
60. Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5* 3 genotype on serum carbamazepine concentrations at steady‐state in Korean epileptic patients. Journal of Clinical Pharmacy and Therapeutics. 2009; Oct; 34(5): 569-74. doi: 10.1111/j.1365-2710.2009.01057.x
61. Al-Gahtany M, Karunakaran G, Munisamy M. Pharmacogenetics of CYP3A5 on Carbamazepine pharmacokinetics in epileptic patients developing toxicity. BMC Genomics. 2014; Apr 2; 15(Suppl 2):P2. doi: 10.1186/1471-2164-15-S2-P2
62. Pham TH, Huynh HT, Vo HT, Tran HM. Effect of CYP3A5 genotypes on serum carbamazepine concentrations at steady-state in Vietnamese epileptic patients. Research Journal of Pharmacy and Technology. 2020; 13(6): 2802-6. doi: 10.5958/0974-360X.2020.00498.9
63. Panomvana D, Traiyawong T, Towanabut S. Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients. Journal of Pharmacy and Pharmaceutical Sciences. 2013; Sep 3; 16(4): 502-10. doi: 10.18433/J3Q888